CDX2 and neoplasm: In recognition of these limitations, we devised an innovative immunohistochemical scoring system for CDX2 expression assessment (CDX2 expression categories 1, 2, and 3), as well as a novel classification of the tumor differentiation patterns (categories 1, 2, 3, and 4), shedding light on the complex molecular heterogeneity of colon cancer.